Mkt Cap$2.24T-0.27%
24h Vol$63.96B
BTC Dom56.1%
ETH Dom9.6%
F&G22Extreme Fear
BTC$62,618.00-0.25% ETH$1,784.25+0.38% USDT$0.9988-0.04% BNB$569.17+0.14% USDC$0.9999+0.01% XRP$1.07-0.61% SOL$75.19-1.62% TRX$0.3249-1.59% FIGR_HELOC$1.03+1.91% HYPE$63.74-2.41% DOGE$0.0723+0.10% USDS$0.99970.00% RAIN$0.0143-0.35% LEO$9.54+0.05% ZEC$507.59-1.85% WBT$54.95-0.04% BTC$62,618.00-0.25% ETH$1,784.25+0.38% USDT$0.9988-0.04% BNB$569.17+0.14% USDC$0.9999+0.01% XRP$1.07-0.61% SOL$75.19-1.62% TRX$0.3249-1.59% FIGR_HELOC$1.03+1.91% HYPE$63.74-2.41% DOGE$0.0723+0.10% USDS$0.99970.00% RAIN$0.0143-0.35% LEO$9.54+0.05% ZEC$507.59-1.85% WBT$54.95-0.04%
News

analysis

Total Stories
4
Section
analysis
Moderna's Shares Gain in Premarket After Promising Study Results of New Flu Shot
Market Analysis

Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results

Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.

Tim FriesJun 30, 20253 min read